Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Kuenzli, Andrea ^a   Bucher, Heiner C ^a   Anand, Inder ^b   Arutiunov, Gregory ^c   Kum, Leo C ^d   McKelvie, Robert ^e   Afzal, Rizwan ^e   White, Michel ^f,g   Nordmann, Lain J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; METOPROLOL; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FUNCTION; META ANALYSIS; MORTALITY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; KIDNEY FAILURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RISK ASSESSMENT; SURVIVAL RATE;

EID: 77956322695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009946     Document Type: Review

References (40)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al. (2006) Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113: e85-151.
3. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, et al. (2000) Long-term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575-1581.
4. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669-677.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-828.
7. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, et al. (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333: 1670-1676.
8. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H (1982) Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4: 966-972.
9. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin IIforming pathways in normal and failing human hearts. Circ Res 66: 883-890.
10. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D (1999) Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 99: 2658-2664.
11. Carson PE (2000) Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 140: 361-366.
12. Latini R, Masson S, Anand I, Judd D, Maggioni AP, et al. (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106: 2454-2458.
13. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT (2003) Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 108: 1306-1309.
14. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, et al. (2002) Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40: 970-975.
15. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM (2007) Adverse effects of combination angiotensin II receptor blockers plus angiotensinconverting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167: 1930-1936.
16. Lakhdar R, Al-Mallah MH, Lanfear DE (2008) Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensinconverting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14: 181-188.
17. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, et al. (2004) Meta-analysis: angiotensin-receptor blockers in chronic heart failure and highrisk acute myocardial infarction. Ann Intern Med 141: 693-704.
18. Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, et al. (2004) Metaanalyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 93: 105-111.
19. Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282: 1054-1060.
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
21. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
24. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.
25. Arutiunov GP, Korsunskaia MI, Cherniavskaia TK, Vershinin AA, et al. (2000) Safety and clinical efficiency of long-term complete blockade of reninangiotensin- aldosterone system in patients with chronic obstructive pulmonary diseases]. Ter Arkh 72: 52-56.
26. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056-1064.
27. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.
28. White M, Lepage S, Lavoie J, De DS, Leblanc MH, et al. (2007) Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 13: 86-94.
29. Kum LC, Yip GW, Lee PW, Lam YY, Wu EB, et al. (2008) Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. Int J Cardiol 125: 16-21.
30. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
31. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, et al. (1999) Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99: 990-992.
32. O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, et al. (2005) Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 7: 650-656.
33. Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, et al. (2005) Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J 150: 323-329.
34. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, et al. (1998) Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of doubleblind, placebo-controlled, randomized trials. Circulation 98: 1184-1191.
35. Bonet S, Agusti A, Arnau JM, Vidal X, Diogene E, et al. (2000) Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 160: 621-627.
36. McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, et al. (2006) Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006 27: 1447-1458.
37. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
38. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553.
39. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551.
40. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.